Any other company would see the stock surge on news like that. But Nader’s missteps (or however folks want to categorize them) and the 13D dispute means nothing shy of trial data, approval, or a partnership will move the pps.

The cancer PR would have sent any other stock way higher. We get good news and close red. Worth remembering how big the short position is here too…